ProCE Banner Activity

Phase II KEYNOTE 158: Pembrolizumab in Advanced Small-Cell Lung Cancer

Slideset Download
Pembrolizumab showed promising antitumor activity in patients with SCLC, particularly those with PD-L1–positive tumors.

Released: June 13, 2018

Expiration: June 12, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Astellas Text

AstraZeneca

Celgene

Eisai

Genentech TEXT Only

Janssen

Merck Oncology

Seagen